64 results about "Pancreatic carcinoma" patented technology

The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Ag1, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Ag1 exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.

A four arm-polyethylene glycol-7-ethyl-10-hydroxycamptothecin conjugate, such as, is disclosed. Methods of making the conjugates and methods of treating mammals using the same are also disclosed.

The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and / or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.

The present invention provides a method for detecting pancreatic carcinoma in a subject. The method includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having the pancreatic carcinoma, thereby detecting pancreatic carcinoma in the subject.

The present invention provides a method for detecting pancreatic carcinoma in a subject. The method includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having the pancreatic carcinoma, thereby detecting pancreatic carcinoma in the subject.

AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface / membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.

The present invention is solid tumor treating medicine composition and belongs to the field of medicine technology. The medicine composition contains melphalan in effective anticancer amount and medicinal supplementary material. The medicinal supplementary material is mainly biocompatible, degradable and absorbable polymer, and during the degradation and absorption of the polymer, melphalan is released slowly to local tumor part to lower the systemic toxic reaction and to maintain local medicine concentration. The present invention has enhanced treating effect. The solid tumor includes cerebral tumor, liver cancer, lung cancer, esophagus cancer, gastric cancer, etc.

The present invention discloses a group of cancer-targeting recombinant oncolytic gene-adenovirus, comprising OncoAd, OncoAd. RGD, and OncoAd. RGD. shPKM2. The invention also discloses a constructionmethod and application of the recombinant oncolytic gene-adenovirus OncoAd. RGD. shPKM2 in preparing of a medicine for treating pancreatic cancer. The recombinant oncolytic gene-adenovirus OncoAd. RGD. shPKM2 can achieves silencing of expression of rate-limiting enzyme gene PKM2 by means of replication of an adenoviral vector, and can play an effective pancreatic cancer killing effect.

The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and / or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol / L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.

The invention relates generally to the changes in gene expression in human tissues from cancer patients. The invention relates specifically to human gene families which are differentially expressed in cancer tissues of breast, colon, esophagus, kidney, liver, lung, lymph node, ovary, pancreas, prostate, rectum, and / or stomach compared to corresponding normal tissues.

Novel antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.

The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and / or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol / L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.

Compositions and methods which indicate an increased risk for pancreatic carcinoma in a test subject are disclosed.

Antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.

The invention provides a monoclonal antibody, which has the following characteristics: 1) the antibody is IgMs immunoglobulin and the light-chain type of the antibody is k-typed; (2) the antigen is identified into a sugar-chain structure with sialylation mucoprotein surface; the monoclonal antibody can specifically identify colorectal adenocarcinoma, endometrial adenocarcinoma and pancreatic carcinoma tissues, can not identify the corresponding normal tissues. Specifically, the monoclonal antibody is formed by the secreting of hybridomas cells with the accession number of CGMCC No. 2643, the amino acid sequence in the heavy-chain variable zone is shown as SEQ ID NO: 1, the amino acid sequence in the light-chain variable zone is shown as SEQ ID NO: 2. The invention also provides a use of the monoclonal antibody in the preparation of a medicament or a kit, wherein the medicament or the kit can be used for the screening of cancer, early-stage diagnosis, treatment monitoring and tumour imaging. In addition, the invention provides a new antibody for inhibitting the growth of the tumor cells of colorectal carcinoma.

An imaging, guidance, planning and treatment system integrated into a single unit or assembly of components, and a method for using same, that can be safely and effectively deployed to treat prostate cancer in all medical settings, including in a physician's office or in an outpatient setting. The system utilizes the novel process of Radio-Frequency Electrical Membrane Breakdown (“EMB” or “RFEMB”) to destroy the cellular membranes of unwanted or cancerous tissue without denaturing the intra-cellular contents of the cells comprising the tissue, thereby exposing tumor antigens and other intra-cellular components which can have an immunologic effect on local or distant cancerous tissue, with or without the addition of immunologic adjutant drugs. The system preferably comprises at least one EMB treatment probe 20, at least one trackable biopsy needle 200, at least one trackable anesthesia needle 300, and at least one controller unit for at least partially automating the treatment process.

The present invention relates to a nucleic acid aptamer which can specifically recognize and bind to pancreatic cancer cells or tissues. The nucleic acid aptamer can bind specifically only to pancreatic cancer cells or tissues without binding to normal pancreatic cancer tissue, and thus can be effectively used as a composition for diagnosing and treating pancreatic cancer. In addition, the nucleic acid aptamer can detect not only the terminal pancreatic cancer cell line Capan-1, but also the early pancreatic cancer cell line Panc-1, and thus can be used for early diagnosis of pancreatic cancer, thereby contributing to increasing the survival rate of pancreatic cancer patients.

The invention relates to a detection device and method of endoscopic-type early pancreatic carcinoma imaging. The device comprises an ultrasonic endoscopic probe, a microwave generator, a microwave radiation unit, a data acquisition card, a computer, a magnetic stirrer, a centrifugal machine and a freeze dryer; the magnetic stirrer, the centrifugal machine and the freeze dryer are used for preparing targeted nanoparticles injected into a human body through veins; the microwave generator emits pulse microwave signals to the human body into which the targeted nanoparticles are injected through the veins through the microwave radiation unit, and utilizes a thermoacoustic effect to stimulate and generate ultrasonic signals; the ultrasonic endoscopic probe is used for receiving the ultrasonic signals and converting the ultrasonic signals into electrical signals, the electrical signals are imported into the computer through the data acquisition card to be subjected to image reconstruction processing, and microwave thermoacoustic imaging is obtained. According to the detection device and method of endoscopic-type early pancreatic carcinoma imaging, the targeted nanoparticles, combined with a microwave thermoacoustic imaging system, are used for early pancreatic carcinoma detection, and not only are toxic and side effects small, but also the accuracy of the early pancreatic carcinoma detection is improved.

The invention relates to uses of a CHIP protein in pancreas cancer early stage diagnosis and prognosis determination, further provides a use of the CHIP protein in the preparation of kits for diagnosing pancreas cancer patients, and especially provides a use of the CHIP protein in the preparation of kits for assessing prognosis of the pancreas cancer patients.

The invention discloses new application of T-2 toxin, namely application of T-2 toxin to preparing drugs for treating pancreatic carcinomas. The effective treatment amount of T-2 toxin is 0.1-20mg / Kg, preferably 0.5-8mg / Kg. The drugs are administrated by implantation, oral administration, intravenous injection, hypodermic injection and intramuscular injection, preferably intra-tumor injection. The inventor builds various solid tumor models and then examines the inhibiting effect of T-2 toxin on the tumors or tumor cells by carrying out intra-tumor injection or culture with cells on T-2 toxin.Experiments show that intra-tumor injection has confirmed curative effect on the tumors, especially the solid tumors hard to excised and drug administration through intra-tumor injection can further reduce the side effect range and degree of T-2 toxin, reduce the side effects of T-2 toxin and improve the inhibiting and killing effects of T-2 toxin on the tumor tissues.

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.

The invention provides an application of USP 49 (ubiquitin-specific protease 49) in preparation of a drug for preventing or treating pancreatic ductal adenocarcinoma. An amino acid sequence of the USP 49 is represented as SEQ ID NO:1. The deubiquitinating enzyme USP49 interacting with FKBP5 protein is provided, a degradation and stabilization mechanism of the FKBP5 protein as well as molecular regulation for an FKBP5-AKT pathway by the deubiquitinating enzyme USP49 is determined, the function and the molecular mechanism of the pathway in the occurrence and development processes of pancreatic ductal adenocarcinoma are provided, new basis is provided for treatment of pancreatic ductal adenocarcinoma, and USP49 has direct guidance significance for personalized medical treatment of pancreatic ductal adenocarcinoma.

The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and / or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.

The invention provides a traditional Chinese medicine composition and an application thereof in preparation of medicines which are used in three-dimensional conformal and intensity modulated radiation therapy for treating advanced pancreatic carcinomas and have synergistic sensitizing and pain relieving effects. The traditional Chinese medicine composition comprises compound Danshen root injection and Qingyi Huaji formula granules. The radiosensitivity of pancreatic carcinomas can be obviously improved, the proliferation inhibition effects on pancreatic carcinomas can be improved and the pains of patients can be relieved by applying the traditional Chinese medicine composition seven days before radiation therapy or while radiation therapy.

The invention discloses a compound with the following structural formula as shown in the specification, and further provides a method of preparing the compound through fermenting and culturing a bacterial strain CGMCC No. 5416 of Phomopsis sp. The compound has good antineoplastic activities for human non-small-cell lung cancer cells, human breast cancer cells, human pancreas cancer cells, human metastasis pancreatic adenocarcinoma cells, human in situ pancreatic adenocarcinoma cells and many other tumor cells, and can be used for preparation of antitumor drugs.

The present invention discloses an sgRNA for knocking out an XPO1 gene, and a base sequence is: 5'-GGATTATGTGAACAGAAAAG-3'; the invention also discloses an XPO1 gene knockout pancreatic cancer cell line, wherein the XPO1 gene sequence lacks two adjacent thymines as compared with a wild type, as shown in a graph 4; and a method of constructing a pancreatic cancer cell line in which the XPO1 gene isknocked out. The pancreatic cancer cell line constructed by the invention regulates the expression of the target gene XPO1 from a genomic layer, compared with the traditional methods, the traditionalmethods mainly focus on the regulation of the transcription level, the method can regulate the target gene XPO1 at multiple levels, and significantly improves the regulation efficiency of the XPO1 gene.

The invention belongs to the technical field of medicine, and particularly relates to traditional Chinese medicine for treating advanced pancreatic carcinoma pain. The traditional Chinese medicine for treating the advanced pancreatic carcinoma pain is prepared by the following traditional Chinese herb active ingredients in parts by weight: 3.5 to 4.5 parts of semen hyoscyami, 4 to 6 parts of dark plum, 4 to 6 parts of golden cypress, 2.5 to 3.5 parts of enriched bittern cake, 2.5 to 3.5 parts of borneol, 3.5 to 4.5 parts of sculellaria barbata, 2.5 to 3.5 parts of asarum sieboldii, 3.5 to 4.5 parts of colophony, 4 to 6 parts of frankincense and 4 to 6 parts of myrrh. The traditional Chinese medicine for treating the advanced pancreatic carcinoma pain has the advantages of high complete remission rate, high effectiveness, quick result and less untoward effect.

The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer, for monitoring the effectiveness of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer treatment, and for drug development.

The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.